Proposed LCD - Implantable Continuous Glucose Monitors (I-CGM) (DL38617)

American Diabetes Association. Statistics About Diabetes. American Diabetes Association. https://www.diabetes.org/resources/statistics/statistics-about-diabetes. Updated March 2018. Accessed February 21, 2020.Department of Health and Human Services. Centers for Medicare & Medicaid Services. CMS Rulings. CMS-1682-R. https://www.cms.gov/Regulations-and-Guidance/Guidance/Rulings/CMS-Rulings-Items/CMS1682R. January 2017. Accessed March 3, 2020.Food and Drug Administration Department of Health & Human Services. P160048/S006 Eversense Continuous Glucose Monitoring System. Food and Drug Administration Department of Health & Human Services. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160048S006c.pdf . Accessed February 27, 2020.Chamberlain JJ, Doyle-Delgado K, Peterson L, Skolnik N. Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes.Annals of Internal Medicine. 2019;171(6):415. doi:10.7326/m19-1638Danne T, Nimri R, Battelino T, et. al. International Consensus on Use of Continuous Glucose Monitoring.Diabetes Care. 2017;40(12):16311640. doi: 10.2337/dc17-1600Food and Drug Administration Department of Health & Human Services. FDA Summary of Safety and Effectiveness Data. Food and Drug Administration Department of Health & Human Services. https://www.fda.gov/media/112153/download. June 2018. Accessed February 24, 2020.ADA. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2019.Diabetes Care. 2019;42:S71-S80.American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes -2017.Diabetes Care. 2017;40:S11-s24.Aronson R, Abitbol A, Tweden KS. First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes.Diabetes Obes Metab. 2019;16. doi:10.1111/dom.13726Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.Diabetes Care. 2019;42:1593-1603.Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.Diabetes Care. 2019 Mar;42:400-405.Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.JAMA. 2017;317(4):371-8.Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial.Ann Intern Med. 2017;167:365-374.Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes.NEJM. 2010; 363(4).Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.NEJM. 2019;381(18):1707-17.Curkendall SM, Zhang B, Oh KS, et al. Incidence and Cost of Hypoglycemia Among Patients with Type 2 Diabetes in the United States: Analysis of a Health Insurance Database.Jcomjournal. 2011;18(10):455-462.de Bock M, Cooper M, Retterath A, et al. Continuous Glucose Monitoring Adherence: Lessons From a Clinical Trial to Predict Outpatient Behavior.J Diabetes Sci Technol. 2016;10(3):627-632.Desai D, Mehta D, Mathias P, Menon G, Schubart UK. Health Care Utilization and Burden of Diabetic Ketoacidosis in the U.S. Over the Past Decade: A Nationwide Analysis.Diabetes Care. 2018;41:1631-1638.Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring.Diabetes Care. 2018;41:2265-74.Engler R, Routh T, Lucisano JY. Adoption Barriers for Continuous Glucose Monitoring and Their Potential Reduction With a Fully Implanted System: Results From Patient Preference Surveys.Clinical Diabetes Journals. 2018;36(1).Goyal RK, Sura SD, Mehta HB. Direct Medical Costs of Hypoglycemia Hospitalization in the United States.Value in Health.20.2017. A399 A811.Haak T, Hanaire H, Aijan R, Hermanns N, Riveline J, Rayman G. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial.Diabetes Ther. 2017;8:5573.Healthcare Cost and Utilization Project National Inpatient Sample 2001-2011. Issued June 2013. Updated November 2015.Implementation of treatment protocols in the Diabetes Control and Complications Trial.Diabetes Care. 1995;18:361-76.IQVIA, Report On Advancing Glycemic Management In Patients With Diabetes.Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial.JAMA. 2017;317:379-87.Mohammed KA, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of Goals in U.S. Diabetes Care, 19992010.N Engl J Med. 2013;368:1613-24.Nathan DM. Long-Term Complications of Diabetes Mellitus.N Engl J Med. 1993;328(23):1676-1685.lafsdttir AF, Polonsky W, Bolinder J, et al. A Rrandomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3).Diabetes Technol Ther. 2018;20(4):274-84.Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self- monitoring of blood glucose: meta-analysis of randomized controlled trials using individual patient data.BMJ. 2011;343:d3805. doi: 10.1136/bmj.d3805Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring Systems Predictive Low Glucose Alert.Diabetes Technol Ther. 2019; 21(4). doi: 10.1089/dia.2018.0359Quilliam BJ, Simeone JC, Osbay AB, Kogut SJ. The Incidence and Costs of Hypoglycemia in Type 2 Diabetes.AJMC. 2011;17(10):673-680.Runge AS, Kennedy L, Brown AS, et al. Does Time-in-Range Matter? Perspectives from People with Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes.Clin Diabetes. 2018;36(2):112119.Tamborlane WV, Beck RW, Bode BW, et al. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes.N Engl J Med. 2008;359:1464-76.Umpierrez GE, Klonoff DC. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital.Diabetes Care. 2018;41:1579-1589.Vigersky RA, McMahon C. The relationship of hemoglobin A1c to time-in-range in patients with diabetes.Diabetes Technol Ther. 2019;21:81- 85.Yeh HC, Brown TT, Maruthur N, et al. Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic Review and Meta-analysis.Ann Intern Med.2012;157:336-47.Yoo EH, Lee SY. Glucose Biosensors: An Overview of Use in Clinical Practice.Sensors. 2010;10:45584576.Pratley RE, Kanapka LG, Rickels MR, et al. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes.JAMA. 2020;323(23):2397-2406. doi:10.1001/jama.2020.6928.